Product description
E.P.T.Q. S100
Low density filler, based on hyaluronic acid, purified stabilized,
100-conditional viscosity index, without lido .
Syringe volume: 1 ml
Needles: 2 x 27 G1/2
Effect duration: 6-8 months
Production: South Korea.
Indications: Correction of superficial irregularities of the skin
profile (fine wrinkles in the forehead and nose bridge, "crow's
feet", fine wrinkles around the mouth, periorbital wrinkles).
Injection depth: middle layer of dermis (2.5-3 mm).
E.P.T.Q. S300
Medium density filler, based on hyaluronic acid, purified
stabilized, 300-conditional viscosity index, without lido .
Syringe volume: 1ml
Needles: 2 x 27 G1/2
Duration of effect: 6-8 months.
Production: South Korea.
Indications: Correction of deep irregularities of the skin profile
(nasolabial folds, perioral wrinkles, wrinkles on the cheeks,
puppet lines; increase in volume and correction of lip contours).
Injection depth: medium / deep dermis.
E.P.T.Q. S500
High density filler, based on hyaluronic acid, purified stabilized,
500-conditional viscosity index, with lido and without.
Syringe volume: 1ml
Needles: 2 x 27 G1/2
Duration of effect: 6-8 months.
Production: South Korea
Indications: Correction of any age-related changes in skin relief
(filling of deep folds), correction of facial areas with volume
deficiency (zygomatic, chin and temporal areas). Injection depth:
medium / deep dermis.
Ingredients
Hyaluronate Sodium (Conc.% < 3.0 %), water (Conc.% ≥ 95 %)
Product spection :
| product name | E.P.T.Q filler |
| HA compostion | 24mg |
| volume | 1ml |
THE HYALURONIC ACID FILLER E.P.T.Q. PRODUCED ACCORDING TO
TECHNOLOGY AND PROCESS OFJETEMA R&D CENTER PROMISES AN EXQUISITE AND SAFE QUALITY.
The e.p.t.q. filler produced according to“The 9 Process” promises an exquisite product that meets safety
standards.
1. Safety of raw ingredients managed in exclusive lines
2. High purity HA content for duration and prevention of swelling
3. High viscoelastic for lift
4. Homogeneous particle implementation technology to complete
sophisticated molding
5. No detection of residual chemical catalyst substance through the
complete crosslinking process
6. Aseptic manufacturing environment to prevent side effects
7. Less than 0.1 EU/ml of Endotoxin
8. Minimizes pain with the same pH, osmotic pressure as the human body
9. Optimized injection pressure for sophisticated procedures
e.p.t.q. keeps endotoxin below 0.1 EU/ml and no detection of
residual BDDE minimizing various side effects that may occur after
the procedure.
1. e.p.t.q. S100 Dermal Filler
2. e.p.t.q. S300 Dermal Filler
3. e.p.t.q. S500 Dermal Filler
